An FDA advisory panel on Monday unanimously agreed that Eli Lilly's Alzheimer's drug, donanemab, has potential benefits for early-stage patients that outweigh the risks.

Alzheimer's drug donanemab gets unanimous backing from FDA advisory panel

2023 was a year of medical breakthroughs. As science progresses, scientists around the world are working hard to improve the quality of human life. This year, several notable, exciting medical advancements made headlines.

Explained | Let's 'Rewind 2023' to medical breakthroughs that gave the world hope

A breakthrough drug known as donanemab has emerged as a significant milestone in the battle against chronic forgetfulness or Alzheimer's disease, after a global trial that confirmed its ability to slow down cognitive decline.

Eli Lilly's new Alzheimer's drug shows promise of slowing down memory decline

In a breakthrough development, a new medicine called donanemab has been shown to have the capability to slow down by a third the progression of Alzheimer's, the most common type of dementia.

Alzheimer's disease slowed down by a third with this new breakthrough medicine

Trouble sleeping may be an early sign of Alzheimer's disease. Most people who are ultimately diagnosed with Alzheimer's find it difficult to fall and stay asleep, years before cognitive issues like memory loss and disorientation start to show up.

Taking sleeping pills lowers levels of Alzheimer's proteins, reveals study

Leqembi, a new Alzheimer's medicine is entering the market; it is the first to have conclusive proof that it can delay the mind-robbing condition by many months.

Explained: FDA approves new Alzheimer's medicine for early-stage patients, but what are the safety concerns?

According to a UK university, researchers have identified 42 genes associated with increased risk of Alzheimer's disease. The research published in the journal Nature Genetics informed that the genome of more than 100,000 people with Alzheimer’s disease were studied and it was compared with 600,000 healthy individuals in order to find out more about genetic makeup.

In major breakthrough, study discovers 42 new genes linked to increased risk of Alzheimer’s disease

A federal panel will decide Friday whether to recommend approval of a controversial but potentially promising Alzheimers drug, which would be the first to come to market in nearly two decades.

Controversial Alzheimer’s drug faces critical test before FDA panel

alzheimer-drug

Alzheimer Drug, News on Alzheimer Drug, stories on Alzheimer Drug, articles on Alzheimer Drug, Alzheimer Drug stories at Wion, Alzheimer Drug news, Alzheimer Drug latest news

alzheimer drug